Small Devices May Pack a Big Punch
According to e-zine Electronics Components World, the global market for portable medical devices is expected to reach $250 million by 2013.
Blog
The Trend Toward a Paperless Hospital
In the second of our series on the Harvard Business Review’s Ten Innovations That Will Transform Medicine, we take a look at evidence-based decision-making.
Retinal Implant Restores Vision to Blind In Clinical Trial
Some of the 11 patients involved in the study could even see well enough to read words and recognize foreign objects.
Somaxon’s Silenor Joins Sleep Aid Market
According to Richard Pascoe, president and CEO of Somaxon, Silenor the first sleep aid that hasn’t been deemed a controlled substance.
FDA to Collaborate with Pharma Companies on New TB Initiative
A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates.
IntelliSoft Group Part of Trend Toward Healthcare Accountability
The Harvard Business Review recently published a list of 10 innovations poised to change the medical industry in 2010.
[Company Profile] Corindus Vascular Robotics
Corindus Vascular Robotics has developed a robotic system to improve percutaneous coronary intervention (PCI) placement and reduce health risks to both the patient and the physician.
Cook Medical Tests Aortic Dissection Treatment In STABLE Trial
The 2003 death of Three’s Company actor John Ritter created new awareness of aortic dissection, a condition that affects tens of thousands of Americans each year.
InterMune Shares Rise On FDA Panel Recommendation
The recommendation caused a 64 percent jump in InterMune stock prices and fueled speculation that the Brisbane, Calif.-based company is ripe for acquisition.
mikehavRx.com News Bytes: $DCTH, $TRA, $POT, $SUPG, $ACCP.OB, $AMLN
Delcath’s Percutaneous Hepatic Perfusion (PHP) technology allows physicians to deliver significantly higher doses of existing chemotherapy drugs to the liver without exposing each patient’s entire body to the anti-cancer drugs.